Featured Items |view more
Artificial Intelligence (AI) has tremendous potential to advance healthcare and improve the lives of everyone. But successful clinical translation requires evaluating the performance of AI models on large and diverse real-world datasets.
Our collaboration’s shared vision and commitment will allow researchers and clinicians to continue to work together to discover and provide new approaches to cancer care.
Classic Hodgkin lymphoma (cHL) is a chemotherapy-sensitive tumor and chemotherapy has been the backbone of treatment for both untreated and relapsed/refractory (R/R) disease
Cancer-related and physical outcomes were similar between longer and shorter regimens, but patients reported less burden on life and finances with shorter treatment regimen.
Diagnostic tools for timely, accurate and inexpensive early cancer detection that can assess risk or monitor response to treatment could help patients get the care they need faster and improve existing care strategies.
Receive Dana-Farber's e-newsletter, Momentum, to learn of advances in cancer research and care, current clinical trials, and upcoming CME programs.
- Breast Cancer Treatment
- Research News Updates
- Faculty Updates
- ASCO 2023 Conference Highlights